Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 1, 2012, Pages 15-26

  Sennik, Devesh ^a   Ahmed, Fahad ^a   Russell Jones, David ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

diabetes mellitus; duration studies; exenatide; GLP 1; incretin; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN;

ACUTE PANCREATITIS; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EVIDENCE BASED PRACTICE; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN RELEASE; METABOLIC DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SATIETY; SIDE EFFECT; SLOW DRUG RELEASE; VOMITING; WEIGHT REDUCTION;

EID: 82955193679     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.11.79     Document Type: Article

References (66)

1. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5), 1047-1053 (2004).
2. Danaei G, Finucane MM, Lu Y et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378, 31-40 (2011).
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359, 1577-1589 (2008).
4. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23(10), 1499-1504 (2000).
5. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustments of therapy. Diabetes Care 32, 193-203 (2009).
6. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with Type 2 diabetes: a preliminary report. Diabetes Care 27(1), 17-20 (2004).
7. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycemia in Type 2 diabetes. Diabet. Med. 25, 245-254 (2008).
8. Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with Type 2 diabetes mellitus. Postgrad. Med. 121(5), 94-107 (2009).
9. Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet. Med. 26, 416-424 (2009).
10. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with Type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. Diabet. Obes. Metab. 10(1), 25-32 (2008).
11. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes mellitus. Diabetologia 47(3), 357-366 (2004).
12. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in Type 2 diabetes: what is up, what is down? Diabetologia 54(1), 10-18 (2011).
13. Jellinger PS. Focus on incretin-based therapies: targeting the core defects of Type 2 diabetes. Postgrad. Med. 123(1), 53-65 (2011).
14. Drucker DJ. The biology of incretin hormones. Cell Metab. 3(3), 153-165 (2006).
15. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144(4), 1444-1455 (2003).
16. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in Type 2 diabetic patients and in healthy subjects. Diabetes 44(9), 1126-1131 (1995).
17. Hribal ML, Sesti G. Liraglutide, the once-daily human GLP-1 analog, in the treatment of Type 2 diabetes. Exp. Rev. Endocrinol. Metab. 5(4), 495-505 (2010).
18. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267(11), 7402-7405 (1992).
19. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) - preclinical and clinical results. Best Pract. Res. Clin. Endocrinol. Metab. 23(4), 463-477 (2009).
20. DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with Type 2 diabetes. Diabetes Care 28, 1092-1100 (2005).
21. Buse JB, Henry RR, Han J et al. Exenatide-113 clinical study group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care 27, 2628-2635 (2004).
22. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with Type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083-1091 (2005).
23. Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with Type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 30, 1448-1460 (2008).
24. Zinman B, Hoogwerf BJ, Duran Garcia S et al. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. 146, 477-485 (2007).
25. Buse JB, Bergenstal RM, Glass LC et al. Use of twice-daily exenatide in basal insulin-treated patients with Type 2 diabetes. A randomised controlled trial. Ann. Int. Med. 154, 103-112 (2011).
26. Derosa G, Maffioli P, Salvadeo SA et al. Exenatide versus glibenclamide in patients with diabetes. Diabet. Technol. Ther. 12, 233-240 (2010).
27. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin. 24, 2943-2952 (2008).
28. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with Type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 30(11), 2767-2772 (2007).
29. Heine RJ, Van Gaal LF, Johns D et al. Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med. 143, 559-569 (2005).
30. Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with Type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin. Ther. 29, 2333-2348 (2007).
31. Nauck MA, Duran S, Kim D et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with Type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50, 259-267 (2007).
32. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with Type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr. Med. Res. Opin. 25(1), 65-75 (2009).
33. Gallwitz B, Böhmer M, Segiet T et al. Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with Type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. Diabetes Care. 34(3), 604-606 (2011).
34. Buse JB, Rosenstock J, Sesti G et al. LEAD-6 study group. Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374, 39-47 (2009).
35. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with Type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24, 275-286 (2008).
36. Ryder REJ, Thong KY, Cull ML, Mills AP, Walton C, Winocour PH. The Association of British clinical diabetologists (ABCD) nationwide exenatide audit. Pract. Diab. Int. 27, 352-357 (2010).
37. Brixner DI, McAdam-Marx C, Ye X et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with Type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes. Metab. 11(12), 1122-1130 (2009).
38. Liutkus J, Rosas Guzman J, Norwood P et al. A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. Diabetes Obes. Metab. 12(12), 1058-1065 (2010).
39. Ahmad SR, Swann J. Exenatide and rare adverse events. N. Engl. J. Med. 358, 1970-1971 (2008).
40. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with Type 2 diabetes: a retrospective cohort study. Diabetes Care 32, 834-838 (2009).
41. Garg R, Chen W, Pendergrass M. Acute pancreatitis in Type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 33(11), 2349-2354 (2010).
42. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of Type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33, 428-433 (2010).
43. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr. Med. Res. Opin. 25, 1019-1027 (2009).
44. Dore DD, Bloomgren GL, Wenten M et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes. Metab. 13(6), 559-566 (2011).
45. Romley J, Peters AL, Goldman D. Risk of pancreatitis from exenatide in the privately-insured population. Presented at: The American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24-28 June 2011 (Abstract 0045-LB).
46. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141(1), 150-156 (2011).
47. Best JH, Hoogwerf BJ, Herman WH et al. Risk of cardiovascular disease events in patients with Type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34(1), 90-95 (2011).
48. Monami M, Cremasco F, Lamanna C et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp. Diabetes Res. 1-10 (2011).
49. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with Type 2 diabetes. Cardiovasc. Diabetol. 10, 22 (2011).
50. Best JH, Little W, Chiquette E, Saunders WB. The risk of heart failure among patients receiving exenatide versus other glucose-lowering medications for Type 2 diabetes: a matched retrospective cohort analysis of the GE Healthcare electronic medical record database. Presented at: The American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24-28 June 2011 (Abstract 1133-P).
51. Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of Type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372(9645), 1240-1250 (2008).
52. Bischoff LA, Jabbour SA, Miller JL. Exenatide once weekly in Type 2 diabetes mellitus. Exp. Opin. Pharmacother. 12(8), 1297-1303 (2011).
53. Bergenstal RM, Wysham C, Macconell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of Type 2 diabetes (DURATION-2): a randomised trial. Lancet 376(9739), 431-439 (2010).
54. Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with Type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375(9733), 2234-2243 (2010).
55. Blevins T, Pullman J, Malloy J et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab. 96(5), 1301-1310 (2011).
56. Cuddihy RM, Russell-Jones D, Hanefeld M et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with Type 2 diabetes. Presented at: The American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24-28 June 2011 (Abstract 0280-OR).
57. Macconell L, Walsh B, Li Y, Pencek R, Maggs D. Exenatide once weekly: Sustained improvement in glycemic control and weight loss through 3 years. Presented at: The American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24-28th June 2011 (Abstract 0969-P).
58. Sager P, Darpo B, Han J et al. Exenatide once weekly did not affect corrected QT interval in patients with Type 2 diabetes. Presented at: The American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24-28 June 2011 (Abstract 1070-P).
59. Macconell L, Malloy J, Huang W, Cirincione B, Shen L, Porter L. Safety and efficacy of once-monthly exenatide over 20 weeks in patients with Type 2 diabetes. Presented at: The American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24-28 June 2011 (Abstract 0046-LB).
60. Waugh N, Cummins E, Royle P et al. Newer agents for blood glucose control in Type 2 diabetes: systematic review and economic evaluation. Health Technol. Assess. 14(36), 1-248 (2010).
61. Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G. Evaluation of exenatide vs. insulin glargine in Type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes Obes. Metab. 11(11), 1068-1079 (2009).
62. Brandle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P, Valentine WJ. Exenatide versus insulin glargine: a cost- effectiveness evaluation in patients with Type 2 diabetes in Switzerland. Int. J. Clin. Pharmacol. Ther. 47(8), 501-515 (2009).
63. Pawaskar M, Zagar A, Sugihara T, Shi L. Healthcare resource utilization and costs assessment of Type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis. J. Med. Econ. 14(1), 16-27 (2011).
64. Kelly AS, Metzig AM, Rudser KD et al. Exenatide as a weight-loss therapy in extremely obese youth without diabetes. Presented at: The American Diabetes Association 71st Scientific Sessions, San Diego, California, USA, 24-28 June 2011 (Abstract 0420-PP).
65. Seetho IW, Jones G, Thomson GA, Fernando DJS. Treating diabetes mellitus in Prader-Willi syndrome with exenatide. Diabetes Res. Clin. Pract. 92(1), E1-E2 (2011).
66. Van Raalte DH, Van Genugten RE, Linssen MM, Ouwens DM, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid- induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 34(2), 412-417 (2011).